Aflibercept in DME: Real-World Effectiveness and Vision Gains

Prof. Andrew Chang highlights real-world data on aflibercept’s effectiveness in treating diabetic macular oedema (DME). Studies such as APELON, FRB and Warfields demonstrate that aflibercept achieves significant and sustained vision gains across various baseline vision levels. In APELON, patients gained an average of 7.8 letters after 12 months, with 45% gaining over 10 letters. The FRB study showed superior outcomes with aflibercept compared to ranibizumab, especially in patients with baseline vision below 69 letters. Warfields revealed sustained gains over 3 years with fewer injections over time. Real-world challenges like patient adherence underscore the need for less burdensome, extended treatment regimens.